{"resourceType": "Evidence", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/comparative-evidence"], "versionId": "66", "lastUpdated": "2025-03-15T18:13:51.413Z"}, "identifier": [{"type": {"text": "FEvIR Object Identifier", "coding": [{"system": "http://terminology.hl7.org/CodeSystem/v2-0203", "code": "ACSN", "display": "Accession ID"}]}, "system": "urn:ietf:rfc:3986", "value": "https://fevir.net/FOI/236987", "assigner": {"display": "Computable Publishing LLC"}}, {"type": {"text": "outcomeId"}, "system": "https://app.magicapp.org/#/guidelines", "value": "109588"}, {"type": {"text": "picoId"}, "system": "https://app.magicapp.org/#/guidelines", "value": "85798"}, {"type": {"text": "sectionId"}, "system": "https://app.magicapp.org/#/guidelines", "value": "73215"}], "name": "Body_weight_from_MAGICapp_109588", "title": "MAGIC-derived Evidence: Body weight with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes", "status": "active", "author": [{"name": "Computable Publishing\u00ae: MAGIC-to-FEvIR Converter"}], "useContext": [{"code": {"system": "https://fevir.net/resources/CodeSystem/179423", "code": "evidence-communication", "display": "Evidence Communication"}, "valueCodeableConcept": {"coding": [{"system": "https://fevir.net/resources/CodeSystem/179423", "code": "ComparativeEvidence", "display": "ComparativeEvidence"}]}}], "variableDefinition": [{"description": "Adults with type 2 diabetes", "variableRole": "population", "observed": {"type": "Group", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "system": "https://fevir.net/FLI", "value": "MAGIC-5288-j1Wqrn-population-group-85394-85798", "assigner": {"display": "Computable Publishing LLC"}}, "display": "Adults with type 2 diabetes and CVD and CKD", "reference": "Group/236947"}}, {"description": "GroupAssignment: SGLT2 inhibitors vs. GLP-1 RA", "variableRole": "exposure", "comparatorCategory": "GLP-1 RA", "observed": {"type": "EvidenceVariable", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "system": "https://fevir.net/FLI", "value": "MAGIC-5288-j1Wqrn-group-assignment-85394-85798", "assigner": {"display": "Computable Publishing LLC"}}, "display": "GroupAssignment: SGLT2 inhibitors vs. GLP-1 RA", "reference": "EvidenceVariable/236950"}}, {"description": "Body weight", "variableRole": "outcome", "observed": {"type": "EvidenceVariable", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "system": "https://fevir.net/FLI", "value": "MAGIC-5288-j1Wqrn-109588", "assigner": {"display": "Computable Publishing LLC"}}, "display": "Body weight", "reference": "EvidenceVariable/236986"}}], "synthesisType": {"text": "SYSTEMATIC_REVIEW"}, "studyDesign": [{"text": "NOTSET"}], "statistic": [{"description": "MD -0.47 Kg (CI95 -0.09 Kg to -0.85 Kg)", "statisticType": {"coding": [{"system": "http://terminology.hl7.org/CodeSystem/statistic-type", "version": "5.0.0-cibuild", "code": "0000457", "display": "Mean Difference"}]}, "quantity": {"value": -0.47, "unit": "Kg"}, "sampleSize": {"numberOfStudies": 2, "numberOfParticipants": 1139}, "attributeEstimate": [{"type": {"text": "CI95"}, "range": {"low": {"value": -0.09, "unit": "Kg"}, "high": {"value": -0.85, "unit": "Kg"}}}]}], "certainty": [{"description": "Due to serious inconsistency", "type": {"coding": [{"system": "http://hl7.org/fhir/certainty-type", "code": "Overall", "display": "Overall certainty"}]}, "rating": {"coding": [{"system": "https://fevir.net/resources/CodeSystem/27834", "code": "RJCS-2004", "display": "Moderate certainty"}]}, "subcomponent": [{"type": {"text": "Risk of Bias"}, "rating": {"text": "NOTSET"}}, {"type": {"text": "Inconsistency"}, "rating": {"text": "SERIOUS"}}, {"type": {"text": "Indirectness"}, "rating": {"text": "NOTSET"}}, {"type": {"text": "Imprecision"}, "rating": {"text": "NOTSET"}}, {"type": {"text": "Publication Bias"}, "rating": {"text": "NOTSET"}}]}], "assertion": "SGLT2 inhibitors probably reduce body weight compared with GLP-1 receptor agonists.", "url": "https://fevir.net/resources/Evidence/236987", "id": "236987", "publisher": "Computable Publishing LLC", "copyright": "https://creativecommons.org/licenses/by-nc-sa/4.0/", "contact": [{"telecom": [{"system": "email", "value": "support@computablepublishing.com"}]}], "extension": [{"extension": [{"url": "type", "valueCode": "part-of"}, {"url": "targetReference", "valueReference": {"type": "Composition", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "system": "https://fevir.net/FLI", "value": "MAGIC-5288-j1Wqrn-conversion-report", "assigner": {"display": "Computable Publishing LLC"}}, "display": "MAGICapp Conversion Report: SGLT2 inhibitors and GLP-1 RA for type 2 diabetes"}}], "url": "http://hl7.org/fhir/uv/ebm/StructureDefinition/relates-to"}], "description": "This Evidence Resource is referenced in an example for the EBMonFHIR Implementation Guide."}